Life Sciences Archive » February, 2020

Life Sciences - February, 2020

295 articles

• Justices Partially Stay Generic Drug Price-Fixing Discovery
• Maverick Funds Sue Bausch Claiming Valeant Price-Gouging
• Sanofi To Pay $12M To End Mass. Medicare Kickback Probe
• Cardinal Health Pays Nearly $9M To Resolve FCPA Claims
• Coronavirus Abounds In Risk Disclosures As Disease Spreads
• FDA Clears First Generic For Daraprim
• Cannabis Bill Roundup: Virginia Is Eyeing Legal Pot
• Mallinckrodt, Express Scripts Can't Get Ill. City's Atty Fee Info
• Illumina Sues Chinese Rival, Again, For 'Brazen Infringement'
• FDA Clashes With Vape Groups As E-Cig Deadline Nears
• Becton Hit With Stock Suit Following $59M Pump Recall
• Fenwick Guides Passage Bio In Upsized, $216M Debut
• Health Hires: Ropes & Gray, K&L Gates, Abrams Fensterman
• J&J Says CEO Questioning Voids $186M Asbestos Trial Award
• Legal Industry Should Pursue AI Prediction Progress
• Judge Says Attys Didn't 'Get The Message,' Can't Drop Clients
• J&J Hit With $9M Asbestos-In-Talc Verdict, First In Fla.
• Surescripts Can't Limit Discovery In FTC Case
• UK Judge Condemns Hasty Patent Law Approach In NJ Talk
• Top DOJ Atty Spotlights Main FCA Target Areas For 2020
• Justices Urged To Ax Fed. Circ. Doctrine Of Equivalents Rule
• Opioid Cos. Slam Atty Fee Proposal That Could Reach $3.3B
• Chancery Tosses Most Of Medical Device Co.'s Sabotage Suit
• Sex Pills Don't Merit Lower VAT As Food, Top EU Court Told
• Quinn Emanuel Adds Ex-Haug Partners' Life Science Chair
• No Jail Time For 2nd Cooperator In PixarBio Fraud Scheme
• King & Spalding Brings On 2 Trial Attys From Orrick
• PTAB Says Prior Art In Pain Treatment Case Is Authentic
• Uncertainty Surrounds Legality Of Different CBD Forms
• Justices Seem Poised To Increase Cos.' Liability Overseas
• Court Certifies RICO, State Antitrust Classes In EpiPen MDL
• Trial Strategy Isn't Malpractice, Brown Rudnick Tells NY Court
• What ACA's Uncertain Future Means For Biologics Patents
• Investor Settlements Remain High As Defendant Sizes Grow
• Zest Soap Maker's $120M Sales OK'd Despite Bidder Dispute
• Ore. Tax Court Nixes Pot Biz's Deduction Before Decoupling
• IVF Investors Can Seek Discovery For Chinese Arbitration
• Real Estate Rumors: Wells, MMG Equity, Horizon Therapeutics
• Veeva Looks To Widen Antitrust Claims Against IQVIA
• Md. Medical Pot Application Process Is Broken, Suit Says
• Jury Kills HIV Test Patent That PTAB Refused To Review
• UnitedHealth Calls Medical Device Co.'s $5M Suit 'Extreme'
• Opioid Judge Rips Pharmacies' 'Ironic' Push To Halt Discovery
• Fed. Circ. Amgen Biosimilar Ruling Raises IP Damages Risk
• Solutions To 4 Common Law Firm Diversity Challenges
• Allergan Inks $51M Deal To End Direct Buyers' Restasis Suit
• Gov't Bid To Undo Arthrex-Based Remand Flops At Fed. Circ.
• 5 AGs To Lead Multistate Probe Into Juul's Marketing Tactics
• Fed. Circ. Won't Rehear Partial Ax Of Horizon Arthritis Drug IP
• Biogen Saleswoman's $6M Firing Award Trimmed To $3.5M
• Ark. Tells High Court ERISA Doesn't Nullify Drug-Payment Law
• Judge Tosses Calif. CBD Co.'s Libel Suit Against Writer
• Seyfarth Brings Litigator To Chicago Health Care Practice
• Feds Say Insys' Kapoor Should Be On Hook For $60M Tab
• When Coronavirus May Trigger SEC Disclosure Requirements
• WilmerHale Snags Capital Markets Partner From Gibson Dunn
• Drug Approval Law Will Likely Deter Pharma Delay Tactics
• Discrimination Cases Are Too Complex For AI Fee Prediction
• Fresenius Loses 'Unduly Speculative' Generic Drug Row
• Mass. High Court Takes Up Boston Drug Test Indemnity Case
• J&J Cuts Last-Minute Deal To Avert Asbestos-In-Talc Trial
• Mallinckrodt Strikes $1.6B Deal To Exit Opioid Suits
• 37 AGs Assail Plaintiffs' Atty Fee Bid In Opioid MDL
• Justices Rebuff Fraud Conviction, ADA Cases
• 9th Circ. Refuses To Block Calif. Pay-For-Delay Ban
• Architect Of Opioid MDL 'Negotiation Class' Dies Suddenly
• Genzyme Medical Device Suit Heads To Mass. High Court
• PTAB Won't Review 2 More HHS HIV-Prevention Patents
• Justices Pass On $550M Self-Dealing Claims In Mesh MDL
• Courts May Clash With Litigants Over Document Review Tech
• Proposed Privacy Laws Put Genetic Testing Cos. In Hot Seat
• High Court Won't Take Fidelity Brokerage Immunity Case
• Latest IPR Trends Mostly Favor Patent Owners
• Bankrupt High Ridge Sells Off Zest, Reach Brands
• CMS, Wilson Sonsini-Led Companies Get SoftBank Backing
• Insys Should Pay Half Of $57M Restitution, Founder Says
• High Court Won't Wade Into Walgreens Religious Bias Case
• Fish & Richardson Names Biosimilars Litigator As New CEO
• Purdue Picks Ex-USDA Head As Monitor In Bankruptcy
• Okla. Plans To Take Opioid Litigation To State Court
• Opioid Cos. Must Face Benefit Plans' Suit In MDL
• AstraZeneca Stuck With FCA Case Over Crestor Marketing
• Ad Watchdog Asks FTC To Review Co.'s CBD Health Claims
• NY Drug Biz Says Insurer Can't 'Flee' Coverage Of Legal Fees
• Vape Co. To Send FDA Deadline Challenge Row To 6th Circ.
• 3rd Circ. Says J&J Must Face Walgreens, Kroger Antitrust Suit
• Melinta's Ch. 11 Plan Docs Approved With New Information
• Trump Heads To India With Tempered Trade Expectations
• NJ Justices Will Take On J&J's Insurance Premium Tax Battle
• Pharma Ruling Broadens Gov't Drug Procurement Options
• Teva Floated As Bellwether In Generic Drug Price-Fixing MDL
• SoClean Wants To Bar 'Knockoff' CPAP Cleaner From Expo
• Feds Want 1st Circ. To Back Convictions Of Ex-NECC Execs
• Health Hires: Davis Wright, Skadden, Holland & Knight
• AI Can't Accurately Predict Case Length And Cost — Yet
• Apotex Suit Against Pfizer Unit Teed Up For State Court
• Ferring Calls Ex-USPTO Chief's Testimony A 'Waste Of Time'
• Schemer Gets 6 Mos. For Playing PixarBio's Fraud 'Game'
• 1st Circ. Won't Nix Fraud Scheme Conviction Over Google Info
• Alcon Can't Clear New Contact Lens Price-Fixing Claims
• Ex-Pfizer VP Owed No Warning On Pension Tax, Fidelity Says
• Leak Triggers Call For Sanctions In Priest's Short-Selling Suit
• Rival Says Allergan Muscle Toner Not As Strong As Claimed
• Patients Can't Revive RICO Claims Against Insulin Makers
• Abbott Can't Nix Suit Over Losing Out On $50M Merger Bonus
• Sens. Tell Azar That FDA's Deadline For Vapes Isn't Flexible
• Utah Justices Revive Suits Alleging Needless Heart Surgeries
• 1st Circ. Revives Worker's FCA Claims Against PharMerica
• 'Vague' Fee Entries Targeted In Boston Scientific FCA Suit
• DST Wants 401(k) Participants' Attys DQ'd In ERISA Fight
• Vape Cos. Tell 5th Circ. FDA Has No Right To Regulate E-Cigs
• IQVIA Calls For Sanctions After Docs 'Magically Disappeared'
• CBD Co. Says It Couldn't Have Stolen Cream Formula
• 20 Attys Picked To Lead Calif. Suits Against Juul
• PTAB Upholds Most Of J&J Unit's Robotic Surgical Patent
• FDA-FTC Biosimilar Push Clarifies Antitrust Stance
• Prop 65 Chemical Labeling Litigation: Trends And Predictions
• Ill. Says Walgreens Bilked It Out Of $19M In Autorefills Fight
• Pot Shop Wants Mass. City Sanctioned For Flouting Injunction
• Glaxo Says FDA Call About Zofran Suits Not 'Covert Lobbying'
• Investor Sues Ex-MiMedx Execs Over Book-Cooking Scheme
• Vanda Pharma Derivative Suit Will Stay In Delaware, On Ice
• 5th Circ. Affirms Lab's $30.6M Tab In Medicare Fraud Suit
• ITC Bans Bio-Rad DNA Product Imports In Patent Case
• Former Teva Exec Calls AGs' Price-Fixing Claims 'Threadbare'
• Hagens, Pomerantz, Rosen To Lead Canopy Stock-Drop Suit
• KKR Lands $200M For New Drug Therapy Research Group
• AI Offers 'Substantial' Pros At USPTO, But Not Without Risks
• States Rip Opioid Judge For Creating Class Action By 'Decree'
• 3 Cos. Join IPO Pipeline With Filings Totaling $286M
• Australis Calls Off Merger With Embattled CBD Co. Folium
• What Health Care FCA Trends Tell Us About The Year Ahead
• Amgen, Amneal Tell Fed. Circ. To Redo Sensipar IP Ruling
• Lawyers Can Build Trust Through The Spoken Word
• Ill. Consumers Say Walgreens Sold Toxic Blood Pressure Drug
• Fed. Circ. Instructive On Transitional Phrases In Patent Claims
• Ex-NFLer Says New Tests Not Needed In Pain Pump Case
• Fenwick-Led Passage Bio Launches $126M IPO
• 'Oblivious' PixarBio CEO Gets 7 Years For $7.5M Stock Fraud
• Nevada Gov. Taps Ex-Chief Justice For State Cannabis Board
• 7th Circ. Won't Revive Antrim Generic-Drug Supply Suit
• Ranbaxy Can't Ask 1st Circ. To Toss Drug Buyers' Suit
• Melinta's Ch 11. Consolidation Is 'Unjustified,' Objectors Say
• FTC Clears $5B Veterinary Hospital Deal With Location Sales
• Insys Execs Owe $57M To Insurers And Victims, Judge Rules
• 1st Circ. Revives Sanofi Insulin Injector Antitrust Case
• What Attys Should Know As Juul Battles Blaze Of Litigation
• Endo Shareholders' Price-Fixing Claims Can't Sway Judge
• Ex-Parchem Worker Dodges Trade Secrets Theft Suit
• Stryker Unit Seeks Ax Of Acantha's IP Marking Failure Suit
• Israeli Drugmaker Can Intervene In $163M Perrigo-US Row
• DOJ's Generic Drug Criminal Probe Snares Ex-Sandoz Exec
• Taxation With Representation: Latham, Skadden, Wachtell
• Fortis Loses 2nd Bid For $425M Post-Merger Drug Payout
• High Court Denies Sanofi Stay During Bid To Expand Arthrex
• Legal Prediction Is Demanding But Not Impossible
• 6th Circ. Halts Nationwide Discovery In Opioid MDL
• PTAB Questions Caris' Word Use In Cancer Treatment Patent
• Chancery Drops Suit Over Biopharma Firm's Cholesterol Drug
• Okla. Tribe Sues Gov't To Offset Opioid 'Bad Men' Harms
• Dental Suppliers Shut Down Patient Antitrust Litigation
• Pharmacies Must Give Patient Ages In Opioid MDL Discovery
• Medical Pot Shouldn't Squelch Pa. Housing Aid, Court Told
• Trends In Recent FCPA And Cartel Cases Against Execs
• Cancer Biotech's Upsized $238M IPO Leads Three Deals
• J&J Unit Settles Noncompete Dispute With Texas-Based Rival
• Class Actions Are A Growing Risk For CBD Cos.
• Life Sciences Group Of The Year: Sidley
• Coronavirus Drug Shows Global Hurdles To Patent Protection
• DLA Piper Adds Product Liability Trio To NY Office
• Akorn Poised For Ch. 11 Sale Following Failed $4.3B Merger
• Calif. Says Man's $78M Roundup Verdict Not Preempted
• Purdue Wants To Make New Opioid Overdose Drug
• Workers Lean On 8th Circ. In 2nd Circ. Express Scripts Suit
• Vape Makers' Challenge To FDA E-Cig Rule Tossed
• Amgen Sues Pfizer, Hospira As Neulasta Patent Feud Widens
• States Lead The Way On Drug Pricing Reform
• Novartis Taps Firms Ready To Pony Up On Diversity — Or Else
• Stimwave Founder Wants Legal Fees For Misconduct Suit
• Fed. Circ. May Limit USPTO's Standing To Intervene
• Fla. Orchid Grower Can't Challenge Medical Pot Licenses
• How Cos. Can Prepare For Heartburn Drug Cancer Claims
• 9th Circ. Halts Teen Suicide Suit Against Allergan
• Ex-Theranos CEO Escapes Charges She Defrauded Doctors
• PTAB Upholds Corcept Patent For Cushing's Syndrome Drug
• Life Sciences Group Of The Year: Latham
• Juul Tried To Recruit Miley Cyrus To Woo Kids, Mass. AG Says
• Justices Halt Ax Of Sanofi's Insulin Patents Over Arthrex
• Danger Of CEO Testimony Clear In $186M J&J Talc Verdict
• Ga. City Joins Chorus Decrying Skyrocketing Baby Med Price
• Shire 'Downright Mean' In Seeking Sanctions, Atty Says
• Saxena White, Bernstein Litowitz Seek Lead In Med Co. Suit
• Hospira Asks Full Fed. Circ. To Settle Split On Inherency
• Diagnostic Co. Investors Try To Seal $2.1M Stock-Drop Deal
• Tenet Settles FCA Suit Over Needless Pacemakers For $1.4M
• UK Supreme Court Weighs Patent Disclosure In Mice Row
• The Implications Of USMCA For Biologic Innovation
• Malpractice Landscape Is Becoming Riskier For BigLaw
• Life Sciences Group Of The Year: King & Spalding
• The Long Odds Of Obtaining IPR Reversals On Issues Of Fact
• Latham Reps Cancer Biotech's Upsized $231M IPO
• Fed Circ. Says Drug Ingredient Doesn't Decide Product Origin
• Ex-Theranos CEO Says Bad Blood Tests Are A 'Fact Of Life'
• Pa. Is Latest State To Claim Juul Marketed E-Cigs To Teens
• Bayer Wants $87M Roundup Cancer Trial Award Overturned
• Hemp Co. Says FDA Statements Don't Make CBD Wares Illegal
• Coronavirus Woes Tip Drug Co. Into Del. Ch. 11
• Judging A Book: Humetewa Reviews 'Guilty People'
• EPA Hemp Pesticide Approval Is A Big Step For Cannabis
• Federal-State Employment Law Divide Reveals Systemic Flaw
• Medical Tech Atty Joins Morgan Lewis As Partner In DC Office
• Melinta Gets Nod For Ch. 11 Auction Starting At $140M
• Acer Therapeutics Tries To Shake Suit Over FDA Rejection
• Life Sciences Group Of The Year: Fish & Richardson
• Pharma Co. Says Insurer HDI Global Won't Cover Ad Suit
• DOJ 'Not Done' With Generic Drug Price-Fixing
• Opioid MDL 'Negotiation Class' Gets Bombarded At 6th Circ.
• Ill. City Says Its Counsel Fees Are Off-Limits In Drug Price Suit
• Health Hires: Bradley Arant, Mintz, Brouse McDowell
• Optum Upends Coventry's $614M PBM Services Contract
• Ex-BioChemics CEO Tries To Slip 'Unfair' Disclosure Order
• CBD Maker Says FDCA Nixes Consumers' Illegal Products Suit
• Biotech Co. Loses Contempt Bid In Bovine Breeding IP Suit
• Life Sciences Group Of The Year: Covington
• UK Litigation Roundup: Here's What You Missed In London
• Takeda Beats Rivals' Challenge To Diabetes Drug Patent
• Twist Bio To Pay $22.5M To End Agilent Trade Secrets Suit
• Bayer Can't Seal Internal Essure Docs, Judge Says
• PharMerica Can't Ditch FCA Suit Over Altered Prescriptions
• J&J Unit Secures Duty-Free Treatment For HIV Drug
• Pay-For-Delay Ban Risks 'Endless Litigation,' 9th Circ. Told
• Deals Rumor Mill: Atotech, Swissport, SoftBank
• More Biotech Firms Going Public Through Blank-Check IPOs
• Takeaways From DOJ Fraud Section's Enforcement Uptick
• Biogen MS Drug Patent Survives Mylan's PTAB Challenge
• The US Product Liability Issues Spreading To The EU
• Casper And 2 Life Sci Cos. Raise Combined $482M In IPOs
• FDA Begins Crackdown On Illegally Marketed E-Cigarettes
• Cyber Liability Insurance Is Gaining Value For Cannabis Cos.
• Mass. Employment Doctrine May Not Help Ex-NuVasive Rep
• J&J Hit With $186M In Punitive Damages For Asbestos In Talc
• Akorn Can't Duck Investor Suits Over Collapsed $4.3B Merger
• PPD Raises Hefty $1.6B In Simpson Thacher-Led IPO
• Mylan Says Amendment Feedback Doesn't Save Sanofi IP
• Zofran Plaintiffs Say GSK Hid FDA Lobbying From Discovery
• JPML Ships Opioid Bellwethers Over Drug Co. Protests
• J&J Rigged Tests To Hide Asbestos In Talc, Jury Told
• Illumina Beats Claims Its Attys Deceived PTAB, Fed. Circ.
• Pot Giant Loses Ohio Licensing Battle With Cresco, Harvest
• ITC To Review Patent Dispute Between Biotech Firms
• Telemedicine Execs Charged In $56M Medicare Fraud Scheme
• Gilead's IPR Bid Over 2 Gov't HIV-Prevention Patents Fails
• Juul Targeted 8 Native American Tribes, House Report Finds
• Pet CBD Maker Hits Hemp Shop With TM Suit Over Name
• DLA Piper Snags 3 IP Attys From Cooley And Impax Labs
• Alphabet's Missteps Offer Crisis Management Case Study
• The Dollars And Sense Of Antitrust Class Certification: Part 1
• For Employers, Devil Is In Details Of Fla. Marijuana Bill
• Casper Sleep Cuts IPO Price While Beam Lifts Target
• Nestlé Unit Invests Another $200M In Food Allergy Drug Co.
• Verana Health Nabs $100M Investment, Buys PYA Analytics
• State Of The Union: Drug Prices, China Deal, Infrastructure
• 3rd Generic Drug Executive Indicted For Price-Fixing
• Fed. Circ. Mulls Reviving Fight Over Opioid Blocker Patent
• FDA Didn't Vet Enviro Impact Of GMO Salmon, Group Claims
• 1 Firm Grabs Spotlight In January Bolstered By Reynolds IPO
• Fed. Circ. Skeptical Sovereign Immunity Bars Cancer IP Suit
• SEC Inks Partial Deal With Ex-Outcome Health Exec
• Philip Morris Escapes Shareholder Suit Over E-Cig Sales
• Walgreens To Pay $7.5M To End Suit Over Fake Pharmacist
• How Emotional Intelligence Can Benefit Transactional Attys
• Insys Execs Say Assumptions Don't Equal $300M Restitution
• Why I Became A Lawyer: Following A Serendipitous Path
• LabCorp Unit Collective Action Needs More Info, Judge Says
• Pa. Court Can't Ban Medical Pot For Probationers, ACLU Says
• 2nd Circ. Asked To Redo 'Deeply Troubling' Blaszczak Ruling
• Magellan Health Taps REIT Pro As New General Counsel
• Duke Can't Get Arthrex-Based Redo Over Muscle Treatment IP
• NM Medical Pot Producers Allowed Tax Deduction On Appeal
• Trustee Flags 'Broad' Releases In Medical Device Firm's Ch. 11
• Feds Unveil Collaborative Push On Biologics Competition
• Bayer Gets Boost As It Preps For Roundup Showdown In Calif.
• Fenwick-Backed Life Sciences Co. Files For $125M IPO
• Strategic Considerations For Litigating Alice Issues At Trial
• 7 Ethics Questions To Ask Before Marketing Your Law Firm
• Womble Bond Nabs Health Care Ace From Nelson Mullins
• Latham, Davis Polk Guide Cancer Biotech's $150M IPO Launch
• NJ High Court Signals Support For Pfizer Arbitration Bid
• Product Liability Defense In The Last Decade — And The Next
• Pfizer Fights Chinese Drugmaker Over Chantix Generic
• Amgen Asks Fed. Circ. To Review Merck's $2.5B Patent Loss
• Fried Frank Assists On Catalent's $315M Deal For Masthercell
• Surescripts Says Conspiracy Claims Outline Valid Agreements
• Purell Sued For Claiming Hand Sanitizer Prevents Flu, Ebola
• Allergan Investors Seek Class Cert. In Implant Stock Drop Suit